The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome according to the results of a major study published online in the Journal of Clinical Oncology. NSCLC is the most common type of lung cancer and represents 85 to 90 percent of all lung [...]
Entries from May 28th, 2008
Study showed Alimta improved survival in certain types of Non-Small Cell Lung Cancer
May 28th, 2008 · No Comments · NSCLC, cancer, competitive intelligence, lung cancer, market intelligence, market trends, oncology
Tags:
Oncology: Renal cell cancer slowed by Novartis’ RAD001
May 16th, 2008 · No Comments · Uncategorized
Nearly two-thirds of renal cell cancer patients taking Novartis AG’s RAD001 (everolimus) had progression of their disease delayed by a year, a significantly better result than in those taking placebo. Everolimus may offer potential new treatment option for patients with advanced kidney cancer who have failed standard therapies. The study assessed patients whose cancer had [...]
Tags:
Market trends: cancer vs. ophthalmology drugs
May 14th, 2008 · No Comments · company news, competitive intelligence, market intelligence, market trends, oncology, ophthalmology
Today I was at the ophthalmologists office getting my eyes tested for some new glasses. The technician and I were chatting convivially about the pros and cons of Avastin versus Lucentis for wet age-related macular degeneration (AMD). Later, while looking at the National Institutes of Health (NIH) site on the internet, I noticed they have [...]
Tags:
AZ and Iressa attempting a comeback in lung cancer?
May 9th, 2008 · No Comments · cancer, company news, competitive intelligence, lung, market intelligence, market trends, oncology
Last week, AstraZeneca announced the submission of a marketing authorisation application to the European Medicines Agency (EMEA) for its oral anti-cancer drug, gefitinib (IRESSA™) as a treatment for locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) in patients who have been pre-treated with platinum-containing chemotherapy. The application was based on data from the Phase [...]
Tags:
Does aspirin lower the risk of breast cancer?
May 3rd, 2008 · No Comments · breast cancer, market intelligence, market trends, oncology, research
A daily aspirin may give women modest protection against the most common type of breast cancer according to a study published in Breast Cancer Research. The finding reinforced earlier research indicating regular use of aspirin might reduce the risk of so-called estrogen receptor-positive breast cancer, which makes up about three quarters of breast cancer cases. [...]
Tags: